Which drug, and when, for patients with BRAF-mutant melanoma?

Abstract

Patients with metastatic melanoma had few treatment options until 2011, when two drugs-ipilimumab and vemurafenib-were approved following advances in the understanding of melanoma biology and tumour immunology. Almost 50% of melanomas harbour mutations in BRAF, mainly at codon 600, which result in constitutive activation of the MAPK pathway. The selective… (More)
DOI: 10.1016/S1470-2045(12)70539-9

Topics

Cite this paper

@article{Jang2013WhichDA, title={Which drug, and when, for patients with BRAF-mutant melanoma?}, author={Sekwon Jang and Michael B. Atkins}, journal={The Lancet. Oncology}, year={2013}, volume={14 2}, pages={e60-9} }